C
Cinclus Pharma
Research based biotech company developing small molecules for the treatment of gastric acid related diseases
About Cinclus Pharma
Cinclus Pharma is a clinical-stage pharmaceutical company focused on developing treatments for gastric acid-related diseases. The company's lead drug candidate, linaprazan glurate, is a novel treatment for erosive gastroesophageal reflux disease (eGERD), a condition that affects a significant portion of the population. Cinclus Pharma's business model revolves around the clinical development and subsequent commercialization of linaprazan glurate.
The company generates revenue through licensing and commercialization agreements. A notable partnership is the €220 million deal with Zentiva to bring linaprazan glurate to the European market. This agreement includes upfront and milestone payments, providing the company with capital to fund its ongoing Phase III clinical trials and other operational expenses. Cinclus Pharma targets the pharmaceutical market, specifically gastroenterology. The company has recently been listed on the Nasdaq Stockholm Main Market, enhancing its visibility and access to capital.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Stockholm, Sweden
- Listing
- IPO 2024
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 84.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Nordic Rising Star 2022, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO CONVERTIBLEOther financing | Mar 2026 | $8.8M | — | Claret Capital Partners | ↗ |
| IPOOther financing | Jun 2024 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $7M | 0% | −$21M | -300.8% |
| 2025 | $7M | +1154.8% | −$21M | -300.8% |
| 2024 | $554K | -24.1% | −$21M | -3774% |
| 2023 | $730K | -30.1% | −$21M | -2863.6% |
| 2022 | $1M | — | −$21M | -2000.6% |
| 2021 | — | — | −$9M | — |
Growth signals
Latest recorded traffic for Cinclus Pharma is 2.2K monthly website visits, down 31.3% over the last three months. Cinclus Pharma's team declined 3.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Claret Capital Partners
Series B and later4 investors entered at this stage
- JSJonas Sjögren
AP4
Recipharm
Bengt Julander
Other known investors4 additional known investors
Eir Ventures
Irrus Investments
Linc Systems
Trill Impact
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cinclus Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cinclus Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.